A Study on the Effect and Safety of BAY 2927088 Tablets in Patients with Solid Tumors and HER2 Mutations
Descrizione riassuntiva dello studio
Researchers are looking for a better way to treat people with solid tumors and HER2-activating mutations. Before a treatment can be approved for use in humans, researchers conduct clinical trials to better understand its safety and effectiveness. In this study, the researchers want to find out how well BAY2927088 works in people with different types of solid tumors with HER2 mutations. This includes tumors in the colon or rectum, the uterus and cervix (lower part of the uterus), the bladder, as well as the biliary tract (including gallbladder and bile ducts) and other types of solid tumors, except for people with advanced non-small cell lung cancer (NSCLC).
Solid tumors may have specific changes or mutations in a gene called human epidermal growth factor receptor 2 (HER2). This leads to the formation of an abnormal form of the HER2 protein in the cancer cells, resulting in increased cell growth. The study treatment, BAY2927088, is intended to block the abnormal HER2 protein, which may potentially stop the spread of cancer. The study will include about 111 participants who are at least 18 years old. All participants will take 20 mg of BAY2927088 in the form of tablets. Participants will receive treatments in 3-week periods, called cycles. These 3-week cycles will be repeated throughout the study. Participants may take BAY2927088 until their cancer worsens, they experience medical problems, or they withdraw from the study.
(BASEC)
Intervento studiato
Adult participants with metastatic or unresectable solid tumors with HER-2-activating mutations, including: colorectal, biliary, bladder, cervical, endometrial, and other solid tumor types.
Participants will receive BAY2927088 20 mg twice daily (BID) until disease progression according to RECIST 1.1, unacceptable toxicity, or until another withdrawal criterion is met.
RECIST 1.1 = Criteria for evaluating response in solid tumors, version 1.1
BID: twice daily
(BASEC)
Malattie studiate
various types of solid tumors with HER2 mutations
(BASEC)
- Documented histologically or cytologically confirmed locally advanced, unresectable or metastatic solid tumor disease (colorectal carcinoma; biliary tumor disease; bladder and urothelial tumor; cervical cancer; endometrial carcinoma; other solid tumor diseases, except for NSCLC).
- The participant must be ≥ 18 years old or have reached the legal minimum age for consent.
- Patients who have previously received an appropriate standard therapy for their tumor type and disease stage or for whom there are no satisfactory alternative treatments.
- Documented activating HER2 mutation.
- At least one measurable lesion that qualifies as a target lesion according to RECIST 1.1 criteria.
(BASEC)
Criteri di esclusione
- Primary diagnosis of non-small cell lung cancer (NSCLC).
- Previous treatment with a HER2 tyrosine kinase inhibitor (TKI).
- Active brain metastases.
- Uncontrolled, severe comorbid condition.
(BASEC)
Luogo dello studio
Berna, Ginevra, Zurigo
(BASEC)
Sponsor
Sophia Birnbaum Bayer (Schweiz) AG Medical Departement Bayer Schweiz, Pharmaceuticals Clinical Research Grubenstrasse 8 8045 Zurich
(BASEC)
Contatto per ulteriori informazioni sullo studio
Persona di contatto in Svizzera
Sophia Birnbaum
+41 44 465 81 11
clinical.operations.switzerland@clutterbayer.comBayer (Schweiz) AG Medical Departement Bayer Schweiz, Pharmaceuticals Clinical Research Grubenstrasse 8 8045 Zurich
(BASEC)
Informazioni scientifiche
non disponibile
Nome del comitato etico approvante (per studi multicentrici solo il comitato principale)
Commissione d'etica Berna
(BASEC)
Data di approvazione del comitato etico
08.05.2025
(BASEC)
ID di studio ICTRP
non disponibile
Titolo ufficiale (approvato dal comitato etico)
A Phase 2 open-label basket study to evaluate the efficacy and safety of orally administered reversible tyrosine kinase inhibitor BAY 2927088 (sevabertinib) in participants with metastatic or unresectable solid tumors with HER2-activating mutations (BASEC)
Titolo accademico
non disponibile
Titolo pubblico
non disponibile
Malattie studiate
non disponibile
Intervento studiato
non disponibile
Tipo di studio
non disponibile
Disegno dello studio
non disponibile
Criteri di inclusione/esclusione
non disponibile
non disponibile
Endpoint primari e secondari
non disponibile
non disponibile
Data di registrazione
non disponibile
Inclusione del primo partecipante
non disponibile
Sponsor secondari
non disponibile
Contatti aggiuntivi
non disponibile
ID secondari
non disponibile
Risultati-Dati individuali dei partecipanti
non disponibile
Ulteriori informazioni sullo studio
non disponibile
Risultati dello studio
Riepilogo dei risultati
non disponibile
Link ai risultati nel registro primario
non disponibile